<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2909222679
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PARALOK 40 mg for I.V. Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Paralok contains the active substance pantoprazole. Paralok is a selective &ldquo;proton pump inhibitor&rdquo;, a medicine which reduces the amount of acid produced in your stomach. It is used for treating acid-related diseases of the stomach and intestine.</p><p>&nbsp;</p><p>This preparation is injected into a vein and will only be given to you if your doctor thinks pantoprazole injections are more suitable for you at the moment than pantoprazole tablets. Tablets will replace your injections as soon as your doctor sees fit.</p><p>&nbsp;</p><p><strong>Paralok</strong><strong> is used for treating adults for:</strong></p><ul><li>Reflux oesophagitis. An inflammation of your oesophagus (the tube which connects your throat to your stomach) accompanied by the regurgitation of stomach acid.</li><li>Stomach and duodenal ulcers.</li><li>Zollinger-Ellison-Syndrome and other conditions producing too much acid in the stomach.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Paralok</strong></p><ul><li>If you are allergic to pantoprazole or to any of the other ingredients of this medicine (listed in section 6).</li><li>If you are allergic to medicines containing other proton pump inhibitors.</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before taking Paralok</p><ul><li>If you have severe liver problems. Please tell your doctor if you have ever had problems with your liver in the past. Your doctor will check your liver enzymes more frequently. In the case of a rise of liver enzymes the treatment should be stopped.</li><li>If you are taking HIV protease inhibitors such as atazanavir (for the treatment of HIV-infection) at the same time as pantoprazole, ask your doctor for specific advice.</li><li>Taking a proton pump inhibitor like pantoprazole, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis (reduced bone density) or if you have been told that you are at risk of getting osteoporosis (for example, if you are taking steroids).</li><li>If you are on Paralok for more than three months, it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</li><li>If you have ever had a skin reaction after treatment with a medicine similar to Paralok that reduces stomach acid.</li><li>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with Paralok. Remember to also mention any other ill-effects like pain in your joints.</li><li>If you are due to have a specific blood test (Chromogranin A).</li></ul><p>&nbsp;</p><p>Tell your doctor immediately, before or after taking this medicine, if you notice any of the following symptoms, which could be a sign of another, more serious, disease:</p><ul><li>An unintentional loss of weight</li><li>Vomiting, particularly if repeated</li><li>Vomiting blood; this may appear as dark coffee grounds in your vomit</li><li>You notice blood in your stools; which may be black or tarry in appearance</li><li>Difficulty in swallowing or pain when swallowing</li><li>You look pale and feel weak (anaemia)</li><li>Chest pain</li><li>Stomach pain</li><li>Severe and/or persistent diarrhoea, because this medicine has been associated with a small increase in infectious diarrhoea.</li></ul><p>&nbsp;</p><p>Your doctor may decide that you need some tests to rule out malignant disease because pantoprazole also alleviates the symptoms of cancer and could cause delay in diagnosing it. If your symptoms continue in spite of your treatment, further investigations will be considered.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Pantoprazole is not recommended for use in children as it has not been proven to work in children below 18 years of age.</p><p>&nbsp;</p><p><strong>Other medicines and Paralok</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>This is because Paralok may influence the effectiveness of other medicines, so tell your doctor if you are taking:</p><ul><li>Medicines such as ketoconazole, itraconazole and posaconazole (used to treat fungal infections) or erlotinib (used for certain types of cancer) because Paralok may stop these and other medicines from working properly.</li><li>Warfarin and phenprocoumon, which affect the thickening, or thinning of the blood. You may need further checks.</li><li>Medicines used to treat HIV-infection, such as atazanavir.</li><li>Methotrexate (used to treat rheumatoid arthritis, psoriasis, and cancer) &ndash; if you are taking methotrexate your doctor may temporarily stop your Paralok treatment because pantoprazole can increase levels of methotrexate in the blood.</li><li>Fluvoxamine (used to treat depression and other psychiatric diseases) &ndash; if you are taking fluvoxamine your doctor may reduce the dose.</li><li>Rifampicin (used to treat infections)</li><li>St John&rsquo;s wort (Hypericum perforatum) (used to treat mild depression)</li></ul><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>There are no adequate data from the use of pantoprazole in pregnant women. Excretion into human milk has been reported.</p><p>&nbsp;</p><p>If you are pregnant or breast feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>You should use this medicine, only if your doctor considers the benefit for you greater than the potential risk for your unborn child or baby.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Pantoprazole has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>If you experience side effects like dizziness or disturbed vision, you should not drive or operate machines.</p><p>&nbsp;</p><p><strong>Paralok contains sodium </strong></p><p>Paralok contains sodium. Each vial of Paralok 40 mg Powder for Solution for Injection contains 2.392 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your nurse or your doctor will administer the daily dose to you as an injection into a vein over a period of 2 - 15 minutes.</p><p>&nbsp;</p><p><strong><em>The recommended dose is:</em></strong></p><p><strong>Adults </strong></p><p><em>For gastric ulcers, duodenal ulcers and reflux </em><em>oesophagitis. </em></p><ul><li>One vial (40 mg pantoprazole) a day.</li></ul><p>&nbsp;</p><p><em>For the long-term treatment of Zollinger-Ellison syndrome and other conditions in which too much stomach acid is produced.</em></p><ul><li>Two vials (80 mg pantoprazole) a day.</li></ul><p>&nbsp;</p><p>Your doctor may later adjust the dose, depending on the amount of stomach acid you produce. If you are prescribed more than two vials (80 mg) a day, the injections will be given in two equal doses. Your doctor may prescribe a temporary dose of more than four vials (160 mg) a day. If your stomach acid level needs to be controlled rapidly, a starting dose of 160 mg (four vials) should be enough to lower the amount of stomach acid sufficiently.</p><p>&nbsp;</p><p><strong>Patients with liver problems </strong></p><p>If you suffer from severe liver problems, the daily injection should be only 20 mg (half a vial).</p><p>&nbsp;</p><p><strong>Use in children and adolescents </strong></p><p>These injections are not recommended for use in children and adolescents under 18 years.</p><p>&nbsp;</p><p><strong>If you use more </strong><strong>Paralok </strong><strong>than you should</strong></p><p>These doses are carefully checked by your nurse or your doctor so an overdose is extremely unlikely. There are no known symptoms of overdose.</p><p>&nbsp;</p><p>If you have any further questions about the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><em>If you get any of the following side effects, tell your doctor immediately</em></strong><em>, <strong>or contact the casualty department at your nearest hospital:</strong></em></p><ul><li>Serious allergic reactions (frequency rare: may affect up to 1 in 1,000 people): swelling of the tongue and/or throat, difficulty in swallowing, hives (nettle rash), difficulties in breathing, allergic facial swelling (Quincke&rsquo;s oedema / angioedema), severe dizziness with very fast heartbeat and heavy sweating.</li><li>Serious skin conditions (frequency not known: frequency cannot be estimated from the available data): You may notice one or more of the following - blistering of the skin and rapid deterioration of your general condition, erosion (including slight bleeding) of eyes, nose, mouth/lips or genitals, or skin sensitivity/rash, particularly in areas of skin exposed to light/the sun. You may also have joint pain or flu-like symptoms, a fever, swollen glands (e.g. in the armpit) and blood tests may show changes in certain white blood cells or liver enzymes (Stevens-Johnson Syndrome, Lyell-Syndrome, Erythema multiforme, Subacute cutaneous lupus erythematosus, Drug reaction with eosinophilia and systemic symptoms (DRESS), Photosensitivity).</li><li>Other serious conditions (frequency not known: frequency cannot be estimated from the available data): yellowing of the skin or whites of the eyes (severe damage to liver cells, jaundice) or fever, rash, and enlarged kidneys sometimes with painful urination, and lower back pain (serious inflammation of the kidneys), possibly leading to kidney failure.</li></ul><p><strong>&nbsp;</strong></p><p><strong><em>Other side effects are: </em></strong></p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>Inflammation of the wall of the vein and blood clotting (thrombophlebitis) where the medicine is injected; benign polyps in the stomach.</li></ul><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people) </strong></p><ul><li>Headache; dizziness; diarrhoea; feeling sick, vomiting; bloating and flatulence (wind); constipation; dry mouth; abdominal pain and discomfort; skin rash, exanthema, eruption; itching; feeling weak, exhausted or generally unwell; sleep disorders; fracture in the hip, wrist or spine.</li></ul><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>Distortion or complete lack of the sense of taste; disturbances in vision such as blurred vision; hives; pain in the joints; muscle pains; weight changes; raised body temperature; high fever; swelling of the extremities (peripheral oedema); allergic reactions; depression; breast enlargement in males.</li></ul><p>&nbsp;</p><p><strong>Very Rare (may affect up to 1 in 10,000 people) </strong></p><ul><li>Disorientation.</li></ul><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data) </strong></p><ul><li>Hallucination, confusion (especially in patients with a history of these symptoms); feeling of tingling, prickling, pins and needles, burning sensation or numbness, rash, possibly with pain in the joints, inflammation in the large bowel, that causes persistent watery diarrhoea.</li></ul><p>&nbsp;</p><p><strong><em>Side effects identified through blood tests: </em></strong></p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>An increase in liver enzymes.</li></ul><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people) </strong></p><ul><li>An increase in bilirubin; increased fat levels in blood; sharp drop in circulating granular white blood cells, associated with high fever.</li></ul><p>&nbsp;</p><p><strong>Very Rare (may affect up to 1 in 10,000 people)</strong></p><ul><li>A reduction in the number of blood platelets, which may cause you to bleed or bruise more than normal; a reduction in the number of white blood cells, which may lead to more frequent infections; coexisting abnormal reduction in the number of red and white blood cells, as well as platelets.</li></ul><p>&nbsp;</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data) </strong></p><ul><li>Decreased level of sodium, magnesium, calcium or potassium in blood (see section 2)</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>Use the reconstituted solution within 12 hours.</p><p>Use the reconstituted and diluted solution within 12 hours.</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 12 hours at not more than 25&deg;C.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice that the visual appearance has changed (e.g., if cloudiness or precipitation is observed).</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pantoprazole sodium sesquihydrate.</p><p>&nbsp;</p><p>Each vial of Paralok 40 mg Powder for Solution for Injection contains 45.18 mg pantoprazole sodium sesquihydrate equivalent to 40 mg pantoprazole.</p><p>&nbsp;</p><p>The other ingredient is sodium hydroxide solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Paralok 40 mg Powder for Solution for Injection is a white to almost white lyophilized powder in 10 ml clear tubular type I glass vials with grey rubber stoppers and aluminum caps.

Pack Size: 1 Vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Batch releaser </strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Bulk manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority. &nbsp;</p><ul><li>United Arab of Emirates</li></ul><p>Pharmacovigilance &amp; Medical Device Section</p><p>P.O. Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>Dubai</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2023; version number Un2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بارالوك على المادة الفعّالة بانتوبرازول. بارالوك عبارة عن &quot;مثبط لمضخة البروتون الانتقائي&quot;، وهو دواء يقلل مقدار الحمض الذي يتم إفرازه في معدتك. يستخدم لعلاج أمراض المعدة والأمعاء المتعلقة بالأحماض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم حقن هذا المستحضر في أحد الأوردة، ولا يتم إعطاؤه لك إلا إذا كان طبيبك يرى أن حقن بانتوبرازول أكثر ملاءمة لك في ذلك الوقت من أقراص بانتوبرازول. تحل الأقراص محل الحقن بمجرد أن يرى طبيبك ذلك مناسباً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يستخدم بارالوك في علاج البالغين في:</strong></p><ul dir="rtl"><li>التهاب المريء الارتجاعي. التهاب في المريء (القناة التي تصل بين الحلق والمعدة) المصحوب بقلس في حمض المعدة.</li><li>قُرَح المعدة والاثنا عشر.</li><li>متلازمة زولينجر إليسون والحالات الأخرى التي يتم فيها إفراز كميات كبيرة جداً من الحمض في المعدة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم بارالوك</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لبانتوبرازول أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li><li>إذا كنت تعاني من حساسية لأدوية أخرى تحتوي على مثبطات لمضخة البروتون.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي أو الممرض قبل استخدام بارالوك:</p><ul dir="rtl"><li>إذا كنت تعاني من مشاكل شديدة في الكبد. يرجى إخبار طبيبك إذا كنت تعاني مسبقاً من مشاكل في الكبد. سيفحص طبيبك مستوى الإنزيمات بالكبد لديك بشكل أكثر تكراراً. يجب إيقاف العلاج في حالة زيادة إنزيمات الكبد.</li><li>إذا كنت تأخذ مثبطات بروتياز فيروس نقص المناعة البشري مثل أتازانافير (لعلاج فيروس نقص المناعة البشري) أثناء استخدام بانتوبرازول، اطلب من طبيبك استشارة محددة.</li><li>قد يؤدي أخذ مثبط لمضخة البروتون مثل بانتوبرازول، وخاصةً على مدى فترة تزيد على سنة، إلى زيادة خطر الإصابة بكسر في الورك، أو المعصم أو العمود الفقري قليلاً. أخبر طبيبك إذا كنت تعاني من مرض هشاشة العظام (انخفاض كثافة العظام) أو إذا تم إخبارك بأنك تعاني من خطر حدوث هشاشة العظام (على سبيل المثال إذا كنت تتناول الستيرويدات)</li><li>إذا أخذت بارالوك لأكثر من ثلاثة أشهر، فمن المحتمل انخفاض مستويات المغنيسيوم في دمك. يمكن ملاحظة انخفاض مستويات المغنيسيوم على هيئة تعب، أو تقلصات لاإرادية في العضلات، أو توهان، أو تشنجات، أو دوخة أو زيادة معدل نبضات القلب. إذا ظهر عليك أي من هذه الأعراض، فيرجى إخبار طبيبك على الفور. يمكن أن يؤدي انخفاض مستويات المغنيسيوم أيضاً إلى انخفاض في مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك إجراء فحوصات دم منتظمة لمراقبة مستويات المغنيسيوم لديك.</li><li>إذا حدث لك في أي وقت مضى رد فعل في الجلد بعد العلاج بدواء مشابه لبارالوك يقلل من حمض المعدة.</li><li>إذا أصبت بطفح جلدي، وخاصةً في المناطق المعرضة للشمس، فأخبر طبيبك بأسرع ما يمكنك، لأنك قد تحتاج إلى إيقاف العلاج باستخدام بارالوك. ولا تنس أيضاً أن تذكر أي آثار مرضية أخرى مثل ألم المفاصل.</li><li>إذا كان من المخطط لك أن تخضع لفحص محدد في الدم (كروموجرانين أ).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور، قبل أخذ هذا الدواء أو بعده، إذا لاحظت أياً من الأعراض التالية التي قد تكون علامة لمرض آخر أكثر خطورة:</p><ul dir="rtl"><li>فقد الوزن غير المتعمد</li><li>القيء، وبخاصة إذا تكرر الأمر</li><li>قيء الدم؛ قد يبدو ذلك قاتم اللون مثل تفل القهوة في القيء</li><li>ملاحظة وجود دم في البراز، قد يكون أسود أو قطراني الشكل</li><li>صعوبة في البلع أو ألم عند البلع</li><li>شحوب وشعور بالضعف (فقر الدم)</li><li>ألم في الصدر</li><li>ألم في المعدة</li><li>الإسهال الشديد و/أو المستمر، لأن هذا الدواء يرتبط بزيادة طفيفة في حدوث الإسهال المعدي.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقرر طبيبك أنك تحتاج إلى إجراء بعض الفحوصات لاستبعاد مرض خبيث لأن بانتوبرازول يخفف أيضاً من أعراض السرطان وقد يسبب تأخراً في تشخيصه. إذا استمرت الأعراض رغم أخذ العلاج، فقد يراعى إجراء فحوصات أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا يوصى باستخدام بانتوبرازول لدى الأطفال حيث لم تثبت فعاليته عند الأطفال دون 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وبارالوك</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أي أدوية أخرى بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لأن بارالوك قد يؤثر على فعالية الأدوية الأخرى، لذلك أخبر طبيبك إذا كنت تأخذ:</p><ul dir="rtl"><li>أدوية مثل كيتوكونازول، وإيتراكونازول وبوساكونازول (تستخدم لعلاج العدوى الفطرية) أو إرلوتينيب (يستخدم لعلاج أنواع معينة من السرطان) لأن بارالوك قد يحول دون عمل هذه الأدوية والأدوية الأخرى بشكل صحيح.</li><li>وارافين والفينوبروكومون اللذان يؤثران على ترقق الدم، أو زيادة سماكته. قد تحتاج إلى فحوصات أخرى.</li><li>الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية، مثل أتازانافير.</li><li>ميثوتريكسات (المستخدم في علاج التهاب المفاصل الروماتويدي، والصدفية، والسرطان) - إذا كنت تتناول ميثوتريكسات، فقد يوقف طبيبك علاجك ببارالوك بشكل مؤقت لأن بانتوبرازول يمكن أن يزيد من مستويات ميثوتركسيت في الدم.</li><li>فلوفوكسامين (المستخدم لعلاج الاكتئاب والأمراض النفسية الأخرى)، إذا كنت تتناول فلوفوكسامين، فقد يقلل طبيبك الجرعة.</li><li>ريفامبيسين (يستخدم لعلاج العدوى)</li><li>نبتة سانت جونز (عشبة العرن) (المستخدمة لعلاج الاكتئاب الخفيف).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">لا توجد بيانات كافية لاستخدام بانتوبرازول لدى النساء الحوامل. تم الإبلاغ عن إفرازه في حليب الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى استشارة طبيبك أو الصيدلي إذا كنت حاملاً أو مرضع، أو تعتقدين بأنك حاملاً أو تخططين لذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ استخدام هذا الدواء فقط إذا رأى طبيبكِ أن الفائدة التي ستحصلين عليها ستكون أكبر من الخطر المحتمل الذي قد يتعرض له الجنين أو الرضيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">ليس لبانتوبرازول أي تأثير أو له تأثير ضئيل على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من آثار جانبية مثل الدوخة أو تشوش الرؤية، فيجب عليك تجنب القيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي بارالوك على الصوديوم </strong></p><p>يحتوي بارالوك على الصوديوم. تحتوي كل زجاجة من بارالوك 40 ملغم مسحوق للحل للحقن على 2.392 ملغم صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل زجاجة، وبذلك يعتبر &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيعطيك الممرض أو الطبيب الجرعة اليومية على شكل حقنة في الوريد خلال فترة تتراوح من دقيقتين إلى 15 دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الجرعة الموصى بها هي:</em></strong></p><p dir="RTL"><strong>بالنسبة للبالغين </strong></p><p dir="RTL"><em>بالنسبة لقرح المعدة، وقرح الاثنا عشر، والتهاب المريء</em> <em>الارتجاعي. </em></p><ul dir="rtl"><li>زجاجة واحدة (40 ملغم بانتوبرازول) يومياً.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>بالنسبة للعلاج طويل المدى لمتلازمة زولينجر إليسون والحالات الأخرى التي يتم فيها إفراز حمض المعدة بكمية كبيرة.</em></p><ul dir="rtl"><li>زجاجتان (80 ملغم بانتوبرازول) يومياً.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد يعدل طبيبك الجرعة لاحقاً، اعتماداً على مقدار حمض المعدة الذي تفرزه. إذا تم وصف أكثر من زجاجتان لك يومياً (80 ملغم)، يتم إعطاء الحقن على جرعتين متساويتين. قد يصف طبيبك جرعة مؤقتة تتجاوز أربع زجاجات (160 ملغم) يومياً. إذا كان يتعين التحكم في مستوى حمض معدتك بسرعة، فإن جرعة البداية التي تبلغ 160 ملغم (أربع زجاجات) من المفترض أن تكون كافية لخفض مقدار حمض المعدة بشكل كافٍ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكبد </strong></p><p dir="RTL">إذا كنت تعاني من مشاكل شديدة في الكبد، يجب أن تكون جرعة الحقن اليومية 20 ملغم فقط (نصف زجاجة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام لدى الأطفال والمراهقين </strong></p><p dir="RTL">لا ينصح باستخدام هذه الحقن لدى الأطفال والمراهقين الأقل من 18 عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت </strong><strong>بارالوك أكثر من اللازم </strong></p><p dir="RTL">يفحص الممرض أو الطبيب الجرعات جيداً لذا من غير المحتمل للغاية استخدام جرعة زائدة. لا توجد أعراض معروفة لاستخدام الجرعة الزائدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب، أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong><em>إذا أصبت بأي من الآثار الجانبية التالية، أخبر الطبيب فوراً</em></strong><em>، <strong>أو اتصل بقسم الطوارئ في أقرب مستشفى لك:</strong></em></p><ul dir="rtl"><li>ردود فعل تحسسية خطيرة (نادرة الشيوع: قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص): تورم في اللسان و/أو الحلق، صعوبة في البلع، شرى (طفح جلدي)، صعوبات في التنفس، تورم تحسسي بالوجه (وذمة وعائية / وذمة كوينكه)، دوخة شديدة تصاحبها سرعة كبيرة في نبضات القلب وتعرّق شديد.</li><li>حالات جلدية خطيرة (غير معروف مدى شيوعها: لا يمكن تقدير شيوعها من البيانات المتاحة): من الممكن أن تلاحظ واحدة أو أكثر من التالي- تبثر الجلد وسرعة تدهور حالتك العامة، وتآكل (يشمل ذلك نزيفاً بسيطاً) في العينين، أو الأنف، أو الفم/الشفتين أو الأعضاء التناسلية أو حساسية/ طفح في الجلد وخاصة في الأماكن المعرضة للضوء/الشمس. من الممكن أن تصاب أيضاً بألم في المفصل أو أعراض مشابهة للإنفلونزا، حمى، تورم الغدد (مثال الإبطين) وقد تظهر فحوصات الدم تغيرات في كريات دم بيضاء معينة أو في أنزيمات الكبد (متلازمة&nbsp;ستيفنز&nbsp;جونسون، متلازمة ليل، حمامى&nbsp;متعددة&nbsp;الأشكال، ذِئْبَةٌ حمامية جلدي تحت الحادة، والتفاعل الدوائي مع كثرة الحمضات والأعراض الجهازية والحساسية للضوء.</li><li>حالات أخرى خطيرة (غير معروف مدى شيوعها: لا يمكن تقدير شيوعها من البيانات المتاحة)، وهي: اصفرار الجلد أو بياض العينين (تلف شديد في خلايا الكبد، يرقان) أو حمّى، وطفح، وتضخم الكلى يصاحبه أحياناً ألم أثناء التبول، وألم أسفل الظهر (التهاب خطير بالكلى)، قد يؤدي إلى فشل كلوي.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>الآثار الجانبية الأخرى هي: </em></strong></p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص)</strong></p><ul dir="rtl"><li>التهاب جدار الوريد وتجلط الدم (التهاب الوريد الخثاري) في المكان الذي يحقن فيه الدواء؛ سلائل حميدة في المعدة.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص) </strong></p><ul dir="rtl"><li>صداع؛ دوخة؛ إسهال؛ شعور بالإعياء، قيء؛ انتفاخ وتطبل البطن (غازات البطن)؛ إمساك؛ جفاف الفم؛ ألم أو مغص في البطن؛ طفح جلدي، طفح ظاهر، طفح؛ حكة؛ شعور بالضعف، أو الإجهاد أو التوعك بوجه عام؛ اضطرابات النوم؛ كسر في الورك أو المعصم، أو العمود الفقري.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص)</strong></p><ul dir="rtl"><li>اختلال حاسة التذوق أو انعدامها بالكامل؛ اضطرابات في الرؤية مثل تشوش الرؤية؛ شرى؛ ألم في المفاصل؛ آلام العضلات؛ تغييرات في الوزن؛ ارتفاع درجة حرارة الجسم؛ حمّى شديدة؛ تورم الأطراف (وذمة محيطية)؛ ردود فعل تحسسية؛ اكتئاب؛ تضخم الثديين لدى الذكور.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية نادرة جداً (قد تؤثر على ما يصل إلى شخص من كل 10000 شخص) </strong></p><ul dir="rtl"><li>التوهان.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير معروفة (لا يمكن تقدير التكرار من البيانات المتاحة) </strong></p><ul dir="rtl"><li>هلوسة، وارتباك (خاصة لدى المرضى الذين كانوا يعانون في السابق من هذه الأعراض)، الشعور بالتنميل والخدران، والوخز والنخز &nbsp;وإحساس بالحرقان أو التنميل، وطفح قد يصاحبه ألم في المفاصل، والتهاب في الأمعاء الغليظة، يسبب إسهالاً مائياً مستمراً.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية التي تم تحديدها من خلال فحوصات الدم: </em></strong></p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><ul dir="rtl"><li>زيادة في إنزيمات الكبد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص) </strong></p><ul dir="rtl"><li>زيادة في البيليروبين؛ زيادة مستويات الدهون في الدم؛ انخفاض حاد في خلايا الدم البيضاء الحبيبية الدوارة يصاحبه حمّى شديدة.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة جداً (قد تؤثر على ما يصل إلى شخص من بين 10000 شخص)</strong></p><ul dir="rtl"><li>انخفاض في عدد الصفائح الدموية، قد يسبب لك نزفاً أو تكدّماً بشكل غير طبيعي؛ انخفاض في عدد خلايا الدم البيضاء قد يؤدي إلى زيادة العدوى المتكررة، انخفاض مزمن غير طبيعي في عدد خلايا الدم البيضاء والحمراء فضلاً عن عدد الصفائح.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية</strong><strong> غير معروفة</strong> <strong>(لا يمكن تقدير التكرار من البيانات المتاحة)</strong></p><ul dir="rtl"><li>انخفاض مستوى الصوديوم، المغنيسيوم، الكالسيوم أو البوتاسيوم في الدم (انظر القسم 2)</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">استخدم المحلول بعد حلّه خلال 12 ساعة.</p><p dir="RTL">استخدم المحلول بعد حلّه وتخفيفه خلال 12 ساعة.</p><p dir="RTL">من وجهة النظر الميكروبيولوجية، يجب استخدام المستحضر على الفور. في حالة عدم استخدامه على الفور، تقع مسؤولية أوقات وظروف التخزين قبل الاستخدام على المستخدم ولن تكون عادةً أكثر من 12 ساعة عند درجة حرارة لا تزيد عن 25&deg; مئوية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت تغيّراً في شكله (مثلاً، إذا تمت ملاحظة تعكّر أو ترّسب).</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي بانتوبرازول الصوديوم نصف ثلاثي الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل زجاجة من بارالوك 40 ملغم مسحوق للحل للحقن على 45.18 ملغم بانتوبرازول الصوديوم نصف ثلاثي الماء يكافئ 40 ملغم بانتوبرازول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المادة الأخرى المستخدمة في التركيبة التصنيعية هي محلول هيدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">بارالوك 40 ملغم مسحوق للحل للحقن هو عبارة عن مسحوق مجفف بالتجميد لونه قريب من الأبيض في زجاجات أنبوبية شفافة بحجم 10 مللتر من النوع رقم واحد مع سدادات مطاطية رمادية اللون وأغطية من الألومينيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق </strong><strong>ومحرر التشغيلة </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية</p><p dir="RTL">هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة للمستحضر النهائي </strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة<br />إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم <img src="data:image/png;base64,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" alt="" width="78" height="23" vspace="0" hspace="0" border="0" style="width:78px;height:23px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />، فارفانسا<br />27056-906 تيروجيم</p><p dir="RTL">سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><ul dir="rtl"><li>الإمارات العربية المتحدة</li></ul><p dir="RTL">قسم اليقظة الدوائية والجهاز الطبي</p><p dir="RTL">صندوق بريد: 1853</p><p dir="RTL">هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">إدارة الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2023، رقم النسخة: Un2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Paralok 40 mg Powder for Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of Paralok 40 mg Powder for Solution for Injection contains 45.18 mg pantoprazole sodium sesquihydrate equivalent to 40 mg pantoprazole.

Excipients with known effect: Sodium. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection.

White to almost white lyophilized powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Protium is indicated for use in adults for:</p><ul><li>Reflux oesophagitis.</li><li>Gastric and duodenal ulcer.</li><li>Zollinger-Ellison-Syndrome and other pathological hyper secretory conditions.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicine should be administered by a healthcare professional and under appropriate medical supervision.</p><p>&nbsp;</p><p>Intravenous administration of pantoprazole is recommended only if oral administration is not appropriate. Data are available on intravenous use for up to 7 days. Therefore, as soon as oral therapy is possible, treatment with Paralok I.V. should be discontinued and 40 mg pantoprazole P.O. should be administered instead.</p><p>&nbsp;</p><p><strong>Posology</strong></p><p><u>Gastric and duodenal ulcer, reflux oesophagitis</u></p><p>The recommended intravenous dose is one vial of Paralok (40 mg pantoprazole) per day.</p><p>&nbsp;</p><p><u>Zollinger-Ellison-Syndrome and other pathological hyper secretory conditions</u></p><p>For the long-term management of Zollinger-Ellison-Syndrome and other pathological hyper secretory conditions patients should start their treatment with a daily dose of 80 mg pantoprazole. Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control.</p><p>&nbsp;</p><p>In case a rapid acid control is required, a starting dose of 2 x 80 mg pantoprazole is sufficient to manage a decrease of acid output into the target range (&lt;10 mEq/h) within one hour in the majority of patients.</p><p>&nbsp;</p><p>Special populations</p><p><em>Patients with hepatic impairment</em></p><p>A daily dose of 20 mg pantoprazole (half a vial of 40 mg pantoprazole) should not be exceeded in patients with severe liver impairment (see section 4.4).</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>No dose adjustment is necessary in patients with impaired renal function (see section 5.2).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is necessary in the elderly (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of pantoprazole 40 mg powder for solution for injection in children aged under 18 years have not been established. Therefore, Paralok 40 mg powder for solution for injection is not recommended for use in patients below 18 years of age.</p><p>&nbsp;</p><p>Currently available data are described in section 5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>A ready-to-use solution is prepared in 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection. For instructions for preparation see section 6.6. The prepared solution may be administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution for injection.</p><p>&nbsp;</p><p>After preparation the solution must be used within 12 hours.</p><p>&nbsp;</p><p>The medicinal product should be administered intravenously over 2 - 15 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles, or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gastric malignancy</u></p><p>Symptomatic response to pantoprazole may mask the symptoms of gastric malignancy and may delay diagnosis. In the presence of any alarm symptom (e. g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded.</p><p>&nbsp;</p><p>Further investigation is to be considered if symptoms persist despite adequate treatment.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>In patients with severe liver impairment, the liver enzymes should be monitored during therapy. In the case of a rise of the liver enzymes, the treatment should be discontinued (see section 4.2).</p><p>&nbsp;</p><p><u>Co-administration with HIV protease inhibitors</u></p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, due to significant reduction in their bioavailability (see section 4.5).</p><p>&nbsp;</p><p><u>Gastrointestinal infections caused by bacteria</u></p><p>Treatment with Paralok may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as&nbsp;<em>Salmonella&nbsp;</em>and&nbsp;<em>Campylobacter</em>&nbsp;or&nbsp;<em>C. difficile</em>.</p><p>&nbsp;</p><p><u>Hypomagnesaemia</u></p><p>Severe hypomagnesaemia has been rarely reported in patients treated with proton pump inhibitors (PPIs) like pantoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. Hypomagnesaemia may lead to hypocalcaemia and/or hypokalaemia (see section 4.8). In most affected patients, hypomagnesaemia (and hypomagnesaemia associated hypocalcaemia and/or hypokalaemia) improved after magnesium replacement and discontinuation of the PPI.</p><p>&nbsp;</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>&nbsp;</p><p><u>Bone fractures</u></p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in the presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p>&nbsp;</p><p><u>Subacute cutaneous lupus erythematosus (SCLE)</u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the healthcare professional should consider stopping Paralok. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>&nbsp;</p><p><u>Interference with Laboratory Tests</u></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Paralok treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p>&nbsp;</p><p><u>Paralok contains sodium </u></p><p>Paralok contains sodium. Each vial contains 2.392 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Medicinal products with pH Dependent Absorption Pharmacokinetics</u></p><p>Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with the absorption of medicinal products where gastric pH is an important determinant of oral bioavailability, e.g. some azole antifungals such as ketoconazole, itraconazole, posaconazole and other medicine such as erlotinib.</p><p>&nbsp;</p><p><u>HIV protease inhibitors</u></p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir due to significant reduction in their bioavailability (see section 4.4).</p><p>&nbsp;</p><p>If the combination of HIV protease inhibitors with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g. virus load) is recommended. A pantoprazole dose of 20 mg per day should not be exceeded. Dosage of the HIV protease inhibitor may need to be adjusted.</p><p>&nbsp;</p><p><u>Coumarin anticoagulants (phenprocoumon or warfarin)</u></p><p>Co-administration of pantoprazole with warfarin or phenprocoumon did not affect the pharmacokinetics of warfarin, phenoprocoumon or INR. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin or phenoprocoumon concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding, and even death. Patients treated with pantoprazole and warfarin or phenprocoumon may need to be monitored for increase in INR and prothrombin time.</p><p>&nbsp;</p><p><u>Methotrexate</u></p><p>Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered.</p><p>&nbsp;</p><p><u>Other interactions studies</u></p><p>Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. The main metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include oxidation by CYP3A4.</p><p>&nbsp;</p><p>Interaction studies with medicinal products also metabolized with these pathways, like carbamazepine, diazepam, glibenclamide, nifedipine, and an oral contraceptive containing levonorgestrel and ethinyl oestradiol, did not reveal clinically significant interactions.</p><p>&nbsp;</p><p>An interaction of pantoprazole with other medicinal products or compounds, which are metabolized using the same enzyme system, cannot be excluded.</p><p>&nbsp;</p><p>Results from a range of interaction studies demonstrate that pantoprazole does not affect the metabolism of active substances metabolised by CYP1A2 (such as caffeine, theophylline), CYP2C9 (such as piroxicam, diclofenac, naproxen), CYP2D6 (such as metoprolol), CYP2E1 (such as ethanol), or does not interfere with p-glycoprotein related absorption of digoxin.</p><p>&nbsp;</p><p>There were no interactions with concomitantly administered antacids.</p><p>&nbsp;</p><p>Interaction studies have also been performed by concomitantly administering pantoprazole with the respective antibiotics (clarithromycin, metronidazole, amoxicillin). No clinically relevant interactions were found.</p><p>&nbsp;</p><p>Medicinal products that inhibit or induce CYP2C19:</p><p>Inhibitors of CYP2C19 such as fluvoxamine could increase the systemic exposure of pantoprazole. A dose reduction may be considered for patients treated long-term with high doses of pantoprazole, or those with hepatic impairment.</p><p>&nbsp;</p><p>Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John&acute;s wort (Hypericum perforatum) may reduce the plasma concentrations of PPIs that are metabolized through these enzyme systems.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or feto/ neonatal toxicity of pantoprazole.</p><p>&nbsp;</p><p>Animal studies have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of Paralok during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Animal studies have shown excretion of pantoprazole in breast milk. There is insufficient information on the excretion of pantoprazole in human milk but excretion into human milk has been reported. A risk to the newborns/infants cannot be excluded. Therefore, a decision on whether to discontinue breast-feeding or to discontinue/abstain from Paralok therapy taking into account the benefit of breast-feeding for the child, and the benefit of Paralok therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There was no evidence of impaired fertility following the administration of pantoprazole in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Adverse drug reactions, such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Approximately 5 % of patients can be expected to experience adverse drug reactions (ADRs).</p><p>&nbsp;</p><p>The table below lists adverse reactions reported with pantoprazole, ranked under the following frequency classification:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>For all adverse reactions reported from post-marketing experience, it is not possible to apply any Adverse Reaction frequency and therefore they are mentioned with a &ldquo;not known&rdquo; frequency.</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 1. Adverse reactions with pantoprazole in clinical trials and post-marketing experience</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top; width:127px"><p><strong>Frequency</strong></p></td><td rowspan="2" style="vertical-align:top; width:56px"><p><strong>Common</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Rare</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Very rare</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top; width:127px"><p><strong>System Organ Class</strong></p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Agranulocytosis</p></td><td style="vertical-align:top"><p>Thrombocytopenia;Leukopenia; Pancytopenia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top; width:127px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity (including anaphylactic reactions and anaphylactic shock)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top; width:127px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyperlipidaemias and lipid increases (triglycerides, cholesterol); Weight changes</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyponatraemia; Hypomagnesaemia (see section 4.4); Hypocalcaemia&nbsp;<sup>(1)</sup>; Hypokalaemia</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top"><p>Sleep disorders</p></td><td style="vertical-align:top"><p>Depression (and all aggravations)</p></td><td style="vertical-align:top"><p>Disorientation (and all aggravations)</p></td><td style="vertical-align:top"><p>Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top"><p>Headache; Dizziness</p></td><td style="vertical-align:top"><p>Taste disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Parasthesia</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Eye disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Disturbances in vision/blurred vision</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top; width:127px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:56px"><p>Fundic gland polyps (benign)</p></td><td style="vertical-align:top"><p>Diarrhoea; Nausea/vomiting; Abdominal distension and bloating; Constipation; Dry mouth; Abdominal pain and discomfort</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Microscopic colitis</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top"><p>Liver enzymes increased (transaminases, &gamma;-GT)</p></td><td style="vertical-align:top"><p>Bilirubin increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatocellular injury; Jaundice; Hepatocellular failure</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Skin and sub-cutaneous tissue disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top"><p>Rash/exanthema/eruption; Pruritus</p></td><td style="vertical-align:top"><p>Urticaria; Angioedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Stevens-Johnson syndrome; Lyell syndrome; Erythema multiforme; Photosensitivity; Subacute cutaneous lupus erythematosus (see section 4.4) Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine (see section 4.4)</p></td><td style="vertical-align:top"><p>Arthralgia; Myalgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscle spasm&nbsp;<sup>(2)</sup></p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tubulointerstitial nephritis (TIN) (with possible progression to renal failure)</p></td></tr><tr><td style="vertical-align:top; width:127px"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:56px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top; width:127px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:56px"><p>Injection site thrombo-phlebitis</p></td><td style="vertical-align:top"><p>Asthenia, fatigue and malaise</p></td><td style="vertical-align:top"><p>Body temperature increased; Oedema peripheral</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>1.&nbsp;Hypocalcaemia and/or hypokalaemia may be related to the occurrence of hypomagnesaemia (see section 4.4)</p><p>&nbsp;</p><p><sup>2.</sup>&nbsp;Muscle spasm as a consequence of electrolyte disturbance</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known symptoms of overdose in man.</p><p>&nbsp;</p><p>Systemic exposure with up to 240 mg administered intravenously over 2 minutes, were well tolerated.</p><p>&nbsp;</p><p>As pantoprazole is extensively protein bound, it is not readily dialysable.</p><p>&nbsp;</p><p>In the case of an overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC02</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells.</p><p>&nbsp;</p><p>Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H+, K+-ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and H2 receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the product is given orally or intravenously.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long-term treatment (simple to adenomatoid hyperplasia). However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.</p><p>&nbsp;</p><p>An influence of a long term treatment with pantoprazole exceeding one year cannot be completely ruled out on endocrine parameters of the thyroid according to results in animal studies.</p><p>&nbsp;</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also, CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.</p><p>&nbsp;</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General pharmacokinetics</u></p><p>Pharmacokinetics does not vary after single or repeated administration. In the dose range of 10 to 80 mg, the plasma kinetics of pantoprazole are linear after both oral and intravenous administration.</p><p>&nbsp;</p><p><u>Distributio</u>n</p><p>Pantoprazole&#39;s serum protein binding is about 98%. Volume of distribution is about 0.15 l/kg.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>The substance is almost exclusively metabolized in the liver. The main metabolic pathway is demethylation by CYP2C19 with subsequent sulphate conjugation, other metabolic pathway includes oxidation by CYP3A4.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Terminal half-life is about 1 hour and clearance is about 0.1 l/h/kg. There were a few cases of subjects with delayed elimination. Because of the specific binding of pantoprazole to the proton pumps of the parietal cell the elimination half-life does not correlate with the much longer duration of action (inhibition of acid secretion).</p><p>&nbsp;</p><p>Renal elimination represents the major route of excretion (about 80%) for the metabolites of pantoprazole; the rest is excreted with the faeces. The main metabolite in both the serum and urine is desmethylpantoprazole which is conjugated with sulphate. The half-life of the main metabolite (about 1.5 hours) is not much longer than that of pantoprazole.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Poor metabolisers</em></p><p>Approximately 3% of the European population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of pantoprazole is probably mainly catalysed by CYP3A4. After a single-dose administration of 40 mg pantoprazole, the mean area under the plasma concentration-time curve was approximately 6 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60%. These findings have no implications for the posology of pantoprazole.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose reduction is recommended when pantoprazole is administered to patients with impaired renal function (incl. dialysis patients). As with healthy subjects, pantoprazole&#39;s half-life is short. Only very small amounts of pantoprazole are dialyzed. Although the main metabolite has a moderately delayed half-life (2 - 3 h), excretion is still rapid and thus accumulation does not occur.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Although for patients with liver cirrhosis (classes A and B according to Child) the half-life values increased to between 7 and 9 h and the AUC values increased by a factor of 5 - 7, the maximum serum concentration only increased slightly by a factor of 1.5 compared with healthy subjects.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>A slight increase in AUC and C<sub>max</sub> in elderly volunteers compared with younger counterparts is also not clinically relevant.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Following administration of single intravenous doses of 0.8 or 1.6 mg/kg pantoprazole to children aged 2 - 16 years there was no significant association between pantoprazole clearance and age or weight. AUC and volume of distribution were in accordance with data from adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard to humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>&nbsp;</p><p>In the two-year carcinogenicity studies in rats neuroendocrine neoplasms were found. In addition, squamous cell papillomas were found in the fore stomach of rats. The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment. In the two-year rodent studies an increased number of liver tumors was observed in rats and in female mice and was interpreted as being due to pantoprazole&#39;s high metabolic rate in the liver.</p><p>&nbsp;</p><p>A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving the highest dose (200 mg/kg). The occurrence of these neoplasms is associated with the pantoprazole-induced changes in the breakdown of thyroxine in the rat liver. As the therapeutic dose in man is low, no harmful effects on the thyroid glands are expected.</p><p>&nbsp;</p><p>In a peri-postnatal rat reproduction study designed to assess bone development, signs of offspring toxicity (mortality, lower mean body weight, lower mean body weight gain and reduced bone growth) were observed at exposures (C<sub>max</sub>) approximately 2x the human clinical exposure. By the end of the recovery phase, bone parameters were similar across groups and body weights were also trending toward reversibility after a drug-free recovery period. The increased mortality has only been reported in pre-weaning rat pups (up to 21 days age) which is estimated to correspond to infants up to the age of 2 years old. The relevance of this finding to the paediatric population is unclear. A previous peri-postnatal study in rats at slightly lower doses found no adverse effects at 3 mg/kg compared with a low dose of 5 mg/kg in this study.</p><p>Investigations revealed no evidence of impaired fertility or teratogenic effects.</p><p>&nbsp;</p><p>Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentration of pantoprazole in the foetus is increased shortly before birth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.

After reconstitution, or reconstitution and dilution, chemical and physical in use stability has been demonstrated for 12 hours at not more than 25°C. 

From a microbiological point of view, the product should be used immediately.

If not used immediately, in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Store in the original in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions of the reconstituted and diluted medicinal product see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml clear tubular type I glass vials with grey lyo-rubber stoppers and aluminum caps.</p><p>&nbsp;</p><p>Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A ready-to-use solution is prepared by injecting 10 ml of 9 mg/ml (0.9%) sodium chloride solution for injection into the vial containing the powder. The appearance of the product after reconstitution is a clear yellowish solution. This solution may be administered directly or may be administered after mixing it with 100 ml 9 mg/ml (0.9%) sodium chloride solution for injection or 50 mg/ml (5%) dextrose solution for injection.</p><p>&nbsp;</p><p>After reconstitution, or reconstitution and dilution, chemical and physical in use stability has been demonstrated for 12 hours at not more than 25&deg;C.</p><p>&nbsp;</p><p>From a microbiological point of view, the product should be used immediately.</p><p>&nbsp;</p><p>Paralok should not be prepared or mixed with solvents other than those stated.</p><p>&nbsp;</p><p>The medicine should be administered intravenously over 2-15 minutes.</p><p>&nbsp;</p><p>The contents of the vial are for single use only. Any product that has remained in the container or the visual appearance of which has changed (e.g. if cloudiness or precipitation is observed) should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11 April 2023 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>